<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7464065\results\search\disease\results.xml">
  <result pre="Aramco Healthcare, [2], grid.415458.90000 0004 1790 6706Specialty Paediatric Medicine, Qatif" exact="Central" post="Hospital, [3], grid.80817.360000 0001 2114 6728Department of Microbiology, Tribhuvan"/>
  <result pre="de las AmÃ©ricas, [9], grid.412256.60000 0001 2176 1069Public Health and" exact="Infection" post="Research Group, Faculty of Health Sciences, Universidad Tecnologica de"/>
  <result pre="data. Abstract A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus" exact="disease" post="(COVID-19), first detected in Wuhan City, Hubei Province, China,"/>
  <result pre="bats. It is highly contagious, causing symptoms like fever, dyspnea," exact="asthenia" post="and pneumonia, thrombocytopenia, and the severely infected patients succumb"/>
  <result pre="been conducted to understand the molecular basis of the SARS-CoV-2" exact="infection" post="and evolution, develop effective therapeutics, antiviral drugs, and vaccines,"/>
  <result pre="antiviral drugs, and vaccines, and to design rapid and confirmatory" exact="viral" post="diagnostics as well as adopt appropriate prevention and control"/>
  <result pre="therapeutic options that can be explored to manage this pandemic" exact="virus infection," post="which would help in valid countering of COVID-19. Keywords"/>
  <result pre="coronavirus (2019-nCoV) by the World Health Organization (WHO) and severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on"/>
  <result pre="(2019-nCoV) by the World Health Organization (WHO) and severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy"/>
  <result pre="by the World Health Organization (WHO) and severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of"/>
  <result pre="International Committee on Taxonomy of Viruses (ICTV) [1â€&quot;4], while the" exact="disease" post="termed as an emerging coronavirus disease 2019 (COVID-19). Since"/>
  <result pre="(ICTV) [1â€&quot;4], while the disease termed as an emerging coronavirus" exact="disease" post="2019 (COVID-19). Since then, this virus has spread to"/>
  <result pre="1), the transmission rate of COVID-19 is much higher, alarming" exact="infection" post="to an average of two to three individuals getting"/>
  <result pre="BCoV) Â 4. Murine coronavirus (MHV) Lineage B: Â 1." exact="Severe" post="acute respiratory syndrome-related SARS-CoV Lineage C: Â 1. Tylonycteris"/>
  <result pre="Â 4. Murine coronavirus (MHV) Lineage B: Â 1. Severe" exact="acute" post="respiratory syndrome-related SARS-CoV Lineage C: Â 1. Tylonycteris bat"/>
  <result pre="4. Murine coronavirus (MHV) Lineage B: Â 1. Severe acute" exact="respiratory" post="syndrome-related SARS-CoV Lineage C: Â 1. Tylonycteris bat coronavirus"/>
  <result pre="2. Pipistrellus bat coronavirus HKU5 (BtCoV-HKU5) Â 3. Middle East" exact="Respiratory" post="Syndrome MERS-CoV Lineage D: Â Rousettus bat coronavirus HKU9"/>
  <result pre="Pipistrellus bat coronavirus HKU5 (BtCoV-HKU5) Â 3. Middle East Respiratory" exact="Syndrome" post="MERS-CoV Lineage D: Â Rousettus bat coronavirus HKU9 (BtCoV-HKU9)"/>
  <result pre="Lineage D: Â Rousettus bat coronavirus HKU9 (BtCoV-HKU9) Gammacoronavirus 1." exact="Avian" post="coronavirus 2. Whale coronavirus SW1 Deltacoronavirus 1. HKU11 2."/>
  <result pre="sold [16, 17]. Wuhan was considered a hotspot for emerging" exact="infectious diseases." post="The news of numerous cases of pneumonia was reported"/>
  <result pre="for emerging infectious diseases. The news of numerous cases of" exact="pneumonia" post="was reported from December 31, 2019, with unknown aetiology"/>
  <result pre="and viruses ofÂ SARSÂ andÂ MERS [19â€&quot;21]. The available yet" exact="limited" post="epidemiological and clinical data for SARS-CoV-2 suggest that the"/>
  <result pre="limited epidemiological and clinical data for SARS-CoV-2 suggest that the" exact="disease" post="spectrum and transmission efficiency of this virus differ from"/>
  <result pre="pangolins and then documented to affect humans leading to mainly" exact="respiratory" post="infection and also to cause multiple system infection, the"/>
  <result pre="and then documented to affect humans leading to mainly respiratory" exact="infection" post="and also to cause multiple system infection, the virus"/>
  <result pre="respiratory infection and also to cause multiple system infection, the" exact="virus infection" post="has also been reported from few animals such as"/>
  <result pre="infection and also to cause multiple system infection, the virus" exact="infection" post="has also been reported from few animals such as"/>
  <result pre="[24]. Infected patients develop symptoms of high fever, dyspnea, pneumonia," exact="chest" post="pain, dry cough, myalgia and diarrhoea as clinical signs"/>
  <result pre="dry cough, myalgia and diarrhoea as clinical signs of the" exact="disease" post="[25, 26] and few other non-respiratory illness symptoms too"/>
  <result pre="related coronaviruses, as well as their biological interactions with other" exact="viral" post="and host proteins, have been explored along with the"/>
  <result pre="potential therapeutic options that could be pursued for therapy despite" exact="limited" post="knowledge of the biology of SARS-CoV-2 such as neutralizing"/>
  <result pre="in bats [39, 40]. The first study to analyze the" exact="viral" post="genome analysis was conducted by the Wuhan Institute of"/>
  <result pre="(TableÂ 2). Samples from seven patients initially complaining of severe" exact="pneumonia" post="were used in the report. It was found that"/>
  <result pre="11,200 9 Rhabdovirus (Rabies) 13,500 11 Paramyxovirus (Mumps) 15,000 9" exact="Reovirus" post="(Rotavirus) 18,500 12 Filovirus (Ebola) 19,000 8 Coronavirus (SARS-CoV-2)"/>
  <result pre="host cell surface receptors resulting in the fusion and subsequent" exact="viral" post="entry. The S protein consists of two functional subunits;"/>
  <result pre="of the host cell and S2 for the fusion of" exact="viral" post="and cellular membranes. Different coronaviruses use different domains present"/>
  <result pre="the formation of multinucleated giant cells. This strategy allows direct" exact="viral" post="spread between cells while avoiding virus-neutralizing antibodies. The S"/>
  <result pre="most abundant structural protein and defines the shape of the" exact="viral" post="envelope[46, 47]. Interaction of S with M protein is"/>
  <result pre="protein is necessary for retention of S in the ER-Golgi" exact="intermediate" post="compartment (ERGIC)/Golgi complex and its incorporation into new virions."/>
  <result pre="contribution from both these domains[50]. It is also involved in" exact="viral" post="assembly and budding [51], resulting in complete virion formation."/>
  <result pre="also involved in viral assembly and budding [51], resulting in" exact="complete" post="virion formation. The genomic sequence alignment among different CoVs"/>
  <result pre="host receptors. SARS-CoV utilizes angiotensin-converting enzyme 2 (ACE2) as the" exact="primary" post="receptor, and MERS-CoV uses dipeptidyl peptidase 4 (DPP4, also"/>
  <result pre="dipeptidyl peptidase 4 (DPP4, also known as CD26) as the" exact="primary" post="receptor. Initial analysis depicted that SARS-CoV-2 has a quite"/>
  <result pre="identified as HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV (which causes severe" exact="acute" post="respiratory syndrome), MERS-CoV (Middle East respiratory syndrome), and now"/>
  <result pre="as HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV (which causes severe acute" exact="respiratory" post="syndrome), MERS-CoV (Middle East respiratory syndrome), and now SARS-CoV-2"/>
  <result pre="SARS-CoV (which causes severe acute respiratory syndrome), MERS-CoV (Middle East" exact="respiratory" post="syndrome), and now SARS-CoV-2 [55]. Currently, the Global Initiative"/>
  <result pre="and SARS-CoV-2) The Coronaviruses were known to cause only mild" exact="respiratory" post="disease in humans, with severe infections in the immunocompromised"/>
  <result pre="SARS-CoV-2) The Coronaviruses were known to cause only mild respiratory" exact="disease" post="in humans, with severe infections in the immunocompromised cases"/>
  <result pre="to cause only mild respiratory disease in humans, with severe" exact="infections" post="in the immunocompromised cases and young population mostly acting"/>
  <result pre="and young population mostly acting as an asymptomatic carrier because" exact="disease" post="symptoms are not much prominent in young ones [56]."/>
  <result pre="horseshoe bats harboring SARS-like viruses directly to humans or via" exact="intermediate" post="hosts, i.e., palm civets or raccoon dogs in the"/>
  <result pre="in the disappearance of SARS-CoV in 2003, with no human" exact="infections" post="reported ever since [21, 63]. The structural and genomic"/>
  <result pre="animals, and have infected humans via dromedary camels acting as" exact="intermediate" post="hosts [20, 64]. SARS-CoV-2 A novel (new) coronavirus (SARS-CoV-2)"/>
  <result pre="above 22 million confirmed cases have been identified [8]. The" exact="disease" post="terrorized over 210 countries/territories/areas with 785,000 deaths, which is"/>
  <result pre="remaining untouched by this virus is meagre because, within a" exact="short" post="period, the virus emerged in many new countries, including"/>
  <result pre="natural reservoirs of the virus [72]. The search for probable" exact="intermediate" post="hosts is going on, keeping the main focus on"/>
  <result pre="be closer to SARS-CoV-2 than bat coronavirus (RaTG13)[73]. Initially, the" exact="disease" post="was thought to be spreading via seafood consumption, but"/>
  <result pre="SARS-CoV in 2002 established CoVs as capable of causing severe" exact="disease" post="in humans. This ability was once again demonstrated by"/>
  <result pre="be the result of spill-over of bat-adapted CoVs into an" exact="intermediate" post="host. They are transmitted from person to person through"/>
  <result pre="intermediate host. They are transmitted from person to person through" exact="respiratory" post="droplets and close contact (https://www.cdc.gov/coronavirus/types.html). The virus is believed"/>
  <result pre="except for SARS-CoV, MERS-CoV, and now SARS-CoV-2. Seldom coronaviruses cause" exact="lower" post="respiratory infection or pneumonia but SARS-CoV-2 causes. Coronaviruses have"/>
  <result pre="for SARS-CoV, MERS-CoV, and now SARS-CoV-2. Seldom coronaviruses cause lower" exact="respiratory" post="infection or pneumonia but SARS-CoV-2 causes. Coronaviruses have seasonal"/>
  <result pre="SARS-CoV, MERS-CoV, and now SARS-CoV-2. Seldom coronaviruses cause lower respiratory" exact="infection" post="or pneumonia but SARS-CoV-2 causes. Coronaviruses have seasonal pattern"/>
  <result pre="and now SARS-CoV-2. Seldom coronaviruses cause lower respiratory infection or" exact="pneumonia" post="but SARS-CoV-2 causes. Coronaviruses have seasonal pattern usually affecting"/>
  <result pre="alarming and accelerating rate. The virus seems lethal, causing severe" exact="acute" post="respiratory symptoms, including fever, dyspnea, asthenia and pneumonia, thrombocytopenia,"/>
  <result pre="and accelerating rate. The virus seems lethal, causing severe acute" exact="respiratory" post="symptoms, including fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and"/>
  <result pre="seems lethal, causing severe acute respiratory symptoms, including fever, dyspnea," exact="asthenia" post="and pneumonia, thrombocytopenia, and increased C-reactive protein and lactate"/>
  <result pre="G-CSF, MCP-1 and MIP-1A [25, 76] resulting into cytokine storm" exact="syndrome" post="followed by severe pulmonary damage and death due to"/>
  <result pre="[25, 76] resulting into cytokine storm syndrome followed by severe" exact="pulmonary" post="damage and death due to respiratory failure. Additionally, all"/>
  <result pre="syndrome followed by severe pulmonary damage and death due to" exact="respiratory" post="failure. Additionally, all the blood cells except neutrophils were"/>
  <result pre="with flaws of a variable degree in the lungs. Additionally," exact="bilateral" post="multilobular subsegmental consolidation, ground-glass opacity with many mottling was"/>
  <result pre="[25, 26]. Recently, myalgia and fatigue are found associated with" exact="rhabdomyolysis" post="in a COVID-19 patient in Wuhan, China suggesting the"/>
  <result pre="reduce the risk of severe outcomes as a result of" exact="rhabdomyolysis" post="[70, 77]. Additionally, COVID-19 patients may also manifest neurological"/>
  <result pre="[30], but even dysgeusia and anosmia [27, 78]. Moreover, SARS-CoV" exact="infection" post="has been reported in the nervous tissue of experimental"/>
  <result pre="patients with heavy involvement of the brainstem. In this context," exact="acute" post="respiratory failure among COVID-19 patients suggests the probable invasion"/>
  <result pre="with heavy involvement of the brainstem. In this context, acute" exact="respiratory" post="failure among COVID-19 patients suggests the probable invasion of"/>
  <result pre="failure among COVID-19 patients suggests the probable invasion of the" exact="brain" post="by SARS-CoV-2 [79].Â Recently, a study supported the neurotropic"/>
  <result pre="patients manifested neurological signs [80]. Those who developed severe pneumonia," exact="pulmonary" post="oedema, hypoxemic respiratory failure, gastrointestinal infection, multiple system failure,"/>
  <result pre="signs [80]. Those who developed severe pneumonia, pulmonary oedema, hypoxemic" exact="respiratory" post="failure, gastrointestinal infection, multiple system failure, or Acute Respiratory"/>
  <result pre="oedema, hypoxemic respiratory failure, gastrointestinal infection, multiple system failure, or" exact="Acute" post="Respiratory Distress Syndrome (ARDS) succumb to the disease. The"/>
  <result pre="hypoxemic respiratory failure, gastrointestinal infection, multiple system failure, or Acute" exact="Respiratory" post="Distress Syndrome (ARDS) succumb to the disease. The threat"/>
  <result pre="failure, gastrointestinal infection, multiple system failure, or Acute Respiratory Distress" exact="Syndrome" post="(ARDS) succumb to the disease. The threat is still"/>
  <result pre="situation [8, 9, 81â€&quot;83]. Besides, there have been reports on" exact="renal failure," post="hepatic and pancreatic damage by SARS-CoV-2 [84, 85]. Destruction"/>
  <result pre="are in use currently for the laboratory confirmation of coronavirus" exact="infection" post="[87â€&quot;89]. Full genome sequencing is the ultimate tool to"/>
  <result pre="outcome and genotyping. Diagnostic tests for SARS-CoV-2/ COVID-19 cases include" exact="viral" post="genome sequencing, RT-PCR, real-time RT-PCR (rRT-qPCR), POCT/bedside testing, reverse"/>
  <result pre="a clinical setting that could lead to increased risk of" exact="disease" post="transmission; hence a rapid, cheap, user-friendly, and sensitive diagnostic"/>
  <result pre="and past epidemics and pandemics situations of Ebola, Zika, Nipah," exact="swine flu," post="avian/bird flu led to make tremendous advances in science"/>
  <result pre="of clinical symptoms like fever, cough, myalgia, and fatigue with" exact="pneumonia" post="[25, 40, 87]. To overcome the symptoms of novel"/>
  <result pre="potential treatment options that could be pursued for therapy despite" exact="limited" post="knowledge of the biology of SARS-CoV-2. Food and Drug"/>
  <result pre="treating COVID-19 patients [115]. Developing neutralizing antibodies In general, the" exact="infection" post="of coronavirus starts with the entry of S protein,"/>
  <result pre="cell membrane and helps the syncytial formation and delivering of" exact="viral" post="nucleocapsids into the cell for further replication [116] and"/>
  <result pre="patients as therapy [121, 122]. FcR has a role in" exact="pulmonary" post="inflammation; hence blocking of FcR activation can reduce inflammatory"/>
  <result pre="immunoglobulins can prove helpful in the therapy of SARS-CoV-2 induced" exact="pulmonary" post="inflammation [123]. S protein was targeted for developing a"/>
  <result pre="developing a neutralizing antibody therapy to combat the new coronavirus" exact="disease" post="[124]. Methods such as phage or yeast display libraries"/>
  <result pre="culture models to confirm that they can neutralize the SARS-CoV-2" exact="disease" post="infection [47, 125, 126]. The alternate strategy of generating"/>
  <result pre="models to confirm that they can neutralize the SARS-CoV-2 disease" exact="infection" post="[47, 125, 126]. The alternate strategy of generating the"/>
  <result pre="immediate in use, it is short-lived. It has limitations of" exact="infection" post="transmission, abnormal reactions, and the possibility of other severe"/>
  <result pre="the possibility of other severe risks like induction of severe" exact="acute" post="lung injury or antibody-dependent enhancement [35, 127]. Oligonucleotides targeting"/>
  <result pre="S-protein of the nCoV-2019 virus using neutralizing antibodies, targeting of" exact="viral" post="genomes could be another option to reduce the infectivity"/>
  <result pre="bat CoV, and existing human CoV in vitro and over" exact="primary" post="human lung epithelial cell cultures and was found promising"/>
  <result pre="existing human CoV in vitro and over primary human lung" exact="epithelial" post="cell cultures and was found promising for treating epidemic"/>
  <result pre="the conserved sequences are essential in siRNA targeting to avoid" exact="viral" post="escape from the oligonucleotides targeting strategy. Second, the delivery"/>
  <result pre="preclinical studies in animal models [131, 132], siRNA candidates in" exact="viral" post="infections like Ebola have failed in clinical trials [133]."/>
  <result pre="studies in animal models [131, 132], siRNA candidates in viral" exact="infections" post="like Ebola have failed in clinical trials [133]. Oligonucleoside"/>
  <result pre="SARS-CoV-2 in vitro [35] effectively. They were able to block" exact="virus infection" post="at low concentrations (micromolar) and showed a high selectivity"/>
  <result pre="in vitro [35] effectively. They were able to block virus" exact="infection" post="at low concentrations (micromolar) and showed a high selectivity"/>
  <result pre="assessed [159]. LAM-002A 9 (apilimod), a drug used to treat" exact="follicular lymphoma" post="and autoimmune diseases have proven effective against SAR-CoV-2. Yale"/>
  <result pre="[159]. LAM-002A 9 (apilimod), a drug used to treat follicular" exact="lymphoma" post="and autoimmune diseases have proven effective against SAR-CoV-2. Yale"/>
  <result pre="9 (apilimod), a drug used to treat follicular lymphoma and" exact="autoimmune diseases" post="have proven effective against SAR-CoV-2. Yale University and AI"/>
  <result pre="most effective and traditional tools used in most of the" exact="infectious" post="outbreaks is the use of serum of patients who"/>
  <result pre="of serum of patients who just recovered from the active" exact="viral infection" post="to treat patients who contract in the future [160]."/>
  <result pre="serum of patients who just recovered from the active viral" exact="infection" post="to treat patients who contract in the future [160]."/>
  <result pre="who contract in the future [160]. Patients recovered from active" exact="viral" post="infections develop a polyclonal immune response to different antigens"/>
  <result pre="contract in the future [160]. Patients recovered from active viral" exact="infections" post="develop a polyclonal immune response to different antigens of"/>
  <result pre="response to different antigens of SARS-CoV-2 as they neutralize active" exact="viral" post="infections. Hence, convalescent-phase plasma can be used as a"/>
  <result pre="supported the use of dromedary immune serum in preventing MERS-CoV" exact="infection" post="[162]. Patients who have 100% recovery from the novel"/>
  <result pre="2014â€&quot;2015 [164]. Plasma-derived from the patients who recovered from the" exact="disease" post="has also been used as therapy [165]. It is"/>
  <result pre="an effective strategy for drug discovery in multiple diseases, including" exact="infectious" post="viral diseases. In combating the nCoV-2019 viral outbreak, the"/>
  <result pre="effective strategy for drug discovery in multiple diseases, including infectious" exact="viral" post="diseases. In combating the nCoV-2019 viral outbreak, the use"/>
  <result pre="multiple diseases, including infectious viral diseases. In combating the nCoV-2019" exact="viral" post="outbreak, the use of already approved small drug molecules"/>
  <result pre="small drug molecules could inhibit the biological aspects of the" exact="viral" post="life cycle like replication, transcriptions, host protein interaction, boosting"/>
  <result pre="like replication, transcriptions, host protein interaction, boosting immunity, among others." exact="Viral" post="polymerase and protease inhibitors of HIV and hepatitis C"/>
  <result pre="among others. Viral polymerase and protease inhibitors of HIV and" exact="hepatitis C" post="virus are two potential antiviral regimens that can be"/>
  <result pre="recombinant interferon-Î²1b (IFN-Î²1b) have been found useful in treating MERS-CoV" exact="infection" post="[110, 170, 171]. Hence, these are being explored as"/>
  <result pre="the combined formula of lopinavir and ritonavir in treating MERS-CoV" exact="infections" post="[173]. Since the novel coronavirus belongs to the same"/>
  <result pre="its revised guidelines for the prevention, diagnosis, and treatment of" exact="pneumonia" post="developed due to COVID-19 infection in the vast populous"/>
  <result pre="prevention, diagnosis, and treatment of pneumonia developed due to COVID-19" exact="infection" post="in the vast populous country [175, 176]. Future research"/>
  <result pre="and mefloquine hydrochloride, were observed to possess anti-SARS-CoV-2 activity with" exact="complete" post="blocking of cell cytopathic effects [177]. Chen et al."/>
  <result pre="it is proposed as a treatment option for ongoing COVID-19" exact="infection" post="[174]. Further, a novel vinylsulfone protease inhibitor suggested treating"/>
  <result pre="known that ACE2 is a crucial player in the coronavirus" exact="infection" post="by promoting cell entry [181]. The metallopeptidase, ACE2, has"/>
  <result pre="ACE2 (hACE2) with comparable affinity found in SARS-CoV SB from" exact="viral" post="isolates associated with the 2002â€&quot;2003 epidemic (i.e., binding with"/>
  <result pre="ACE2 is an important drug target for the treatment of" exact="cardiovascular" post="and kidney diseases [85, 184]. Recently, Lei et al."/>
  <result pre="an important drug target for the treatment of cardiovascular and" exact="kidney diseases" post="[85, 184]. Recently, Lei et al. [185] demonstrated the"/>
  <result pre="(RAS) could be a useful therapeutic option in reducing the" exact="lung inflammation" post="and treating pneumonia in COVID-19 patients [186, 187]. The"/>
  <result pre="useful therapeutic option in reducing the lung inflammation and treating" exact="pneumonia" post="in COVID-19 patients [186, 187]. The virus attachment through"/>
  <result pre="be taken care of as patients may not always develop" exact="bacterial" post="complications [50]. Other trials involved the use of lopinavirâ€&quot;ritonavir"/>
  <result pre="detrimental to COVID-19 patients [65, 194]. Besides, to manage the" exact="hypoxia" post="in the COVID-19 patientsâ€™ ventilation and salvage therapy are"/>
  <result pre="used as an immunostimulant for animals and humans affected by" exact="viral" post="infections like the influenza virus, West Nile virus, hepatitis"/>
  <result pre="as an immunostimulant for animals and humans affected by viral" exact="infections" post="like the influenza virus, West Nile virus, hepatitis virus,"/>
  <result pre="by viral infections like the influenza virus, West Nile virus," exact="hepatitis" post="virus, herpes virus, papillomavirus, and HIV. In this context,"/>
  <result pre="infections like the influenza virus, West Nile virus, hepatitis virus," exact="herpes" post="virus, papillomavirus, and HIV. In this context, AHCC may"/>
  <result pre="against SARS-CoV-2 [49]. For safe and successful treatment of severe" exact="respiratory" post="illness in infants and children, the probability of atelectasis"/>
  <result pre="severe respiratory illness in infants and children, the probability of" exact="atelectasis" post="due to invasive or non-invasive ventilation support and risks"/>
  <result pre="glycopeptide antibiotic against staphylococci [196], has been recommended in complicated" exact="infections" post="of COVID-19 and Staphylococcus aureus [197, 198]. It has"/>
  <result pre="proven effective in treating clinical conditions of patients. Danoprevir, a" exact="viral" post="protease inhibitor, has also been used in a clinical"/>
  <result pre="response in rhesus macaques. Data showed that a significantly reduced" exact="viral" post="load in bronchoalveolar lavage fluid and lower respiratory tract"/>
  <result pre="a significantly reduced viral load in bronchoalveolar lavage fluid and" exact="lower" post="respiratory tract tissue of vaccinated rhesus macaques challenged with"/>
  <result pre="significantly reduced viral load in bronchoalveolar lavage fluid and lower" exact="respiratory" post="tract tissue of vaccinated rhesus macaques challenged with SARS-CoV-2"/>
  <result pre="macaques challenged with SARS-CoV-2 compared with control animals, and no" exact="pneumonia" post="was observed in vaccinated animals. However, there was no"/>
  <result pre="between vaccinated and control animals. Importantly, no evidence of immune-enhanced" exact="disease" post="following viral challenge in vaccinated animals was observed. Safety,"/>
  <result pre="and control animals. Importantly, no evidence of immune-enhanced disease following" exact="viral" post="challenge in vaccinated animals was observed. Safety, immunogenicity and"/>
  <result pre="was observed. Safety, immunogenicity and efficacy of ChAdOx1 nCoV-19 against" exact="symptomatic" post="PCR-positive COVID-19 illness will now be assessed in randomised"/>
  <result pre="major groups like live attenuated virus vaccines, DNA vaccines, non-replicating" exact="viral" post="vector vaccines, replicating viral vector vaccines, and subunit vaccines"/>
  <result pre="attenuated virus vaccines, DNA vaccines, non-replicating viral vector vaccines, replicating" exact="viral" post="vector vaccines, and subunit vaccines [215]. A DNA plasmid-based"/>
  <result pre="sequences is proving beneficial for subunit vaccine development [72, 219]." exact="Structural" post="proteins of SARS-CoV-2, including envelope (E), membrane (M), nucleocapsid"/>
  <result pre="can prevent virus entry and hence a strategy for controlling" exact="viral infection" post="[201]. Targeting S protein can both develop both cellular"/>
  <result pre="prevent virus entry and hence a strategy for controlling viral" exact="infection" post="[201]. Targeting S protein can both develop both cellular"/>
  <result pre="explored as possible modes of administration [201]. DNA vaccines, chimeric" exact="viral" post="vaccines, and membrane vesicle-vaccines are valuable options [201]. An"/>
  <result pre="has been delivered to the National Institute of Allergy and" exact="Infectious" post="Diseases. That was developed 42 days after the DNA"/>
  <result pre="SARS-CoV, MERS-CoV, and SARS-CoV-2 [121, 230, 231]. These can be" exact="viral" post="protease inhibitors [231], enzyme inhibitors [232], antivirals [228, 233],"/>
  <result pre="233], immunomodulatory [234], and treatment adjuvants [235]. That is the" exact="primary" post="class that has attracted most of the patents [121]."/>
  <result pre="TableÂ 3 Patents on methodologies of different aspects of coronaviruses" exact="Patent" post="no. Date Basis Research/patent title Findings References 2016-07-20 EP3045181A1"/>
  <result pre="2016-07-20 EP3045181A1 Vaccine A novel vaccine against the middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV) The invention relates an immunogenic composition"/>
  <result pre="EP3045181A1 Vaccine A novel vaccine against the middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV) The invention relates an immunogenic composition comprising"/>
  <result pre="Der Hoek [227] 2012-07-05 ES2384445T3 Vaccine Spike protein of canine" exact="respiratory" post="coronavirus (crcv), polymerase, and hemaglutinin/esterase A vaccine composition for"/>
  <result pre="vaccine composition for vaccinating dogs, the composition comprising: a canine" exact="respiratory" post="coronavirus (CRCV) containing a Spike (S) protein having a"/>
  <result pre="Brownlie et al. [239] 2017-10-12 WO2017176596A1 Vaccine Multivalent vaccines for" exact="rabies" post="virus and coronaviruses The present disclosure provides methods and"/>
  <result pre="for inducing an immune response that confers dual protection against" exact="infections" post="by either or both of a rabies virus and"/>
  <result pre="dual protection against infections by either or both of a" exact="rabies" post="virus and a coronavirus, and which can be used"/>
  <result pre="coronavirus, and which can be used therapeutically for an existing" exact="infection" post="with the rabies virus and a coronavirus to treat"/>
  <result pre="can be used therapeutically for an existing infection with the" exact="rabies" post="virus and a coronavirus to treat at least one"/>
  <result pre="infecting agents. In particular, the present disclosure provides a recombinant" exact="rabies" post="virus vector comprising a nucleotide sequence encoding at least"/>
  <result pre="and methods of using the same to treat or prevent" exact="viral infection" post="and disease from coronaviruses, caliciviruses, and picornaviruses Chang et"/>
  <result pre="methods of using the same to treat or prevent viral" exact="infection" post="and disease from coronaviruses, caliciviruses, and picornaviruses Chang et"/>
  <result pre="using the same to treat or prevent viral infection and" exact="disease" post="from coronaviruses, caliciviruses, and picornaviruses Chang et al. [261]"/>
  <result pre="materials and methods for the treatment of patients with coronavirus" exact="infection" post="and the control of zoonotic disease outbreaks using broad-spectrum"/>
  <result pre="of patients with coronavirus infection and the control of zoonotic" exact="disease" post="outbreaks using broad-spectrum non-covalent coronavirus protease inhibitors Emma et"/>
  <result pre="protease inhibitors Emma et al. [231] 2017-08-03 WO2017129975A1 Vaccine Attenuated" exact="infectious" post="bronchitis virus The present invention provides a live, attenuated"/>
  <result pre="inhibitors Emma et al. [231] 2017-08-03 WO2017129975A1 Vaccine Attenuated infectious" exact="bronchitis" post="virus The present invention provides a live, attenuated coronavirus"/>
  <result pre="as a vaccine for treating and preventing disease, such as" exact="infectious" post="bronchitis, in a subject Bickerton et al. [262] 2019-12-05"/>
  <result pre="human subject suffering from or at risk of developing an" exact="autoimmune disease," post="disorder or condition Administering a pharmaceutical composition, wherein the"/>
  <result pre="tolerance in the subject against the antigen that mediates the" exact="autoimmune disease," post="disorder or condition Jordi et al. [234] 2020-01-02 US20200002370A1"/>
  <result pre="of Interferon Genes) is beneficial, for example, inflammation, allergic and" exact="autoimmune diseases," post="infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants"/>
  <result pre="Genes) is beneficial, for example, inflammation, allergic and autoimmune diseases," exact="infectious diseases," post="cancer, pre-cancerous syndromes and as vaccine adjuvants Adams and"/>
  <result pre="immunogen. Infiltrating immune cells respond to the RNA by expressing" exact="type I" post="interferons and pro-inflammatory cytokines, which produce a local adjuvant"/>
  <result pre="al. [263] 2018-12-18 US10154985B2 Treatment Method for treating a glycoprotein-related" exact="disease" post="A method for treating a glycoprotein-related disease is disclosed,"/>
  <result pre="treating a glycoprotein-related disease A method for treating a glycoprotein-related" exact="disease" post="is disclosed, which comprises: administering a first effective amount"/>
  <result pre="a composition. Applications for the composition include, but are not" exact="limited" post="to, use in the preparation of antibodies against the"/>
  <result pre="WO2017010835A1 Drug/treatment Use of radotinib for prevention or treatment of" exact="viral" post="respiratory disease The present invention relates to a new"/>
  <result pre="Drug/treatment Use of radotinib for prevention or treatment of viral" exact="respiratory" post="disease The present invention relates to a new use"/>
  <result pre="Use of radotinib for prevention or treatment of viral respiratory" exact="disease" post="The present invention relates to a new use of"/>
  <result pre="Chemical FormulaÂ 1 (radotinib) in the prevention or treatment of" exact="viral" post="respiratory disease. According to the present invention, a compound"/>
  <result pre="FormulaÂ 1 (radotinib) in the prevention or treatment of viral" exact="respiratory" post="disease. According to the present invention, a compound of"/>
  <result pre="a useful antiviral agent for the prevention or treatment of" exact="disease" post="caused by infection of the Middle East respiratory syndrome-coronavirus"/>
  <result pre="agent for the prevention or treatment of disease caused by" exact="infection" post="of the Middle East respiratory syndrome-coronavirus (MERS-CoV). Kim et"/>
  <result pre="treatment of disease caused by infection of the Middle East" exact="respiratory" post="syndrome-coronavirus (MERS-CoV). Kim et al. [232] 2016-06-15 CN105671209A Diagnosis"/>
  <result pre="and ns12.9) to be cloned into human coronavirus OC43 full-length" exact="infectious" post="clone pBAC-OC43FL, and four ranilla luciferase gene expression recombinant"/>
  <result pre="in the virus growth curve, the inserted reporter gene is" exact="stable" post="in a serial passage process, and the virus rOC43-ns2DelRluc"/>
  <result pre="in preparation of drugs used for preventing or treating coronavirus" exact="infection" post="Rao et al. [266] 2016-09-01 WO2016138160A1 Recombinant peptides/antibodies treatment"/>
  <result pre="et al. [266] 2016-09-01 WO2016138160A1 Recombinant peptides/antibodies treatment Middle east" exact="respiratory" post="syndrome coronavirus immunogens, antibodies, and their use Methods of"/>
  <result pre="al. [266] 2016-09-01 WO2016138160A1 Recombinant peptides/antibodies treatment Middle east respiratory" exact="syndrome" post="coronavirus immunogens, antibodies, and their use Methods of inducing"/>
  <result pre="an immune response in a subject to the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the"/>
  <result pre="immune response in a subject to the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) are provided. In several embodiments, the immune"/>
  <result pre="is a protective immune response that inhibits or prevents MERS-CoV" exact="infection" post="in the subject. Recombinant MERS-CoV polypeptides and nucleic acid"/>
  <result pre="as well as methods of preventing and treating a MERS-CoV" exact="infection" post="in a subject Graham et al. [267] 2016-06-01 CN105624122A"/>
  <result pre="et al. [267] 2016-06-01 CN105624122A Mutant virus as a vaccine" exact="Avian" post="infectious bronchitis virus natural mutant The invention relates to"/>
  <result pre="al. [267] 2016-06-01 CN105624122A Mutant virus as a vaccine Avian" exact="infectious" post="bronchitis virus natural mutant The invention relates to the"/>
  <result pre="[267] 2016-06-01 CN105624122A Mutant virus as a vaccine Avian infectious" exact="bronchitis" post="virus natural mutant The invention relates to the field"/>
  <result pre="the field of virology. It aims to provide an avian" exact="infectious" post="bronchitis virus natural mutant, kept in China General Microbiological"/>
  <result pre="field of virology. It aims to provide an avian infectious" exact="bronchitis" post="virus natural mutant, kept in China General Microbiological Culture"/>
  <result pre="an avian infectious bronchitis virus natural mutant, kept in China" exact="General" post="Microbiological Culture Collection Center, named infectious bronchitis virus, and"/>
  <result pre="mutant, kept in China General Microbiological Culture Collection Center, named" exact="infectious" post="bronchitis virus, and collected under CGMCC No. 11491. A"/>
  <result pre="kept in China General Microbiological Culture Collection Center, named infectious" exact="bronchitis" post="virus, and collected under CGMCC No. 11491. A genome"/>
  <result pre="of this mutant is 27, 541 lbp in length, a" exact="complete" post="genome sequence of the mutant is as shown in"/>
  <result pre="and treatment Suppress polypeptide and its application of human coronavirusâ€™s" exact="infection" post="broad spectrum The invention belongs to the biomedicine field."/>
  <result pre="particular, to polypeptide and its application of human coronary virusâ€™s" exact="disease" post="can be contained a broad spectrum. The S2 regions"/>
  <result pre="syncretizing mechanisms provide can be to the polypeptide of the" exact="infection" post="with broad-spectrum inhibitory action of two or more human"/>
  <result pre="[269] 2018-02-13 US9889194B Immunogenic proteins Immunogenic composition for MERS coronavirus" exact="infection" post="Described herein are immunogenic compositions for preventing infection with"/>
  <result pre="MERS coronavirus infection Described herein are immunogenic compositions for preventing" exact="infection" post="with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the"/>
  <result pre="herein are immunogenic compositions for preventing infection with Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at"/>
  <result pre="are immunogenic compositions for preventing infection with Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least"/>
  <result pre="[270] 2019-11-21 US20190351049A1 Spike protein Human Antibodies to Middle East" exact="Respiratory" post="Syndrome - Coronavirus Spike Protein The present invention provides"/>
  <result pre="2019-11-21 US20190351049A1 Spike protein Human Antibodies to Middle East Respiratory" exact="Syndrome" post="- Coronavirus Spike Protein The present invention provides monoclonal"/>
  <result pre="Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike" exact="Protein" post="The present invention provides monoclonal antibodies that bind to"/>
  <result pre="invention provides monoclonal antibodies that bind to the Middle East" exact="Respiratory" post="Syndromeâ€&quot;Coronavirus (MERS-CoV) spike protein and methods of use. In"/>
  <result pre="activity, thus providing a means of treating or preventingÂ MERSÂ" exact="infection" post="in humans. In some embodiments, the invention provides for"/>
  <result pre="The invention relates to chimeric AAV capsids targeted to the" exact="central nervous system," post="virus vectors comprising the same, and methods of using"/>
  <result pre="same, and methods of using the vectors to target the" exact="central nervous system." post="The invention further relates to chimeric AAV capsids targeted"/>
  <result pre="the speed of response against a pathogenic antigen or a" exact="cancer" post="antigen. A two-step prime-boost method whereby the immune system"/>
  <result pre="al. [273] 2019-10-17 US20190314497A1 Treatment Compositions and methods for treating" exact="viral" post="infections through stimulated innate immunity in combination with antiviral"/>
  <result pre="[273] 2019-10-17 US20190314497A1 Treatment Compositions and methods for treating viral" exact="infections" post="through stimulated innate immunity in combination with antiviral compounds"/>
  <result pre="compounds Embodiments are directed to compositions and methods for treating" exact="viral" post="infections Dickey et al. [274] 2019-03-12 US10226434B2 Treatment Design,"/>
  <result pre="Embodiments are directed to compositions and methods for treating viral" exact="infections" post="Dickey et al. [274] 2019-03-12 US10226434B2 Treatment Design, synthesis,"/>
  <result pre="directed to compounds, techniques, and compositions for treating or preventing" exact="viral" post="infections using nucleosides analogues. Specifically, the present invention provides"/>
  <result pre="to compounds, techniques, and compositions for treating or preventing viral" exact="infections" post="using nucleosides analogues. Specifically, the present invention provides for"/>
  <result pre="vaccine Disclosed herein is a vaccine comprising a Middle East" exact="Respiratory" post="Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a"/>
  <result pre="Disclosed herein is a vaccine comprising a Middle East Respiratory" exact="Syndrome" post="coronavirus (MERS-CoV) antigen. The antigen can be a consensus"/>
  <result pre="2019-09-10 US10406229B2 Vaccine Methods and compositions related to inhibition of" exact="viral" post="entry Disclosed herein are compositions and arrangements for inhibiting"/>
  <result pre="viral entry Disclosed herein are compositions and arrangements for inhibiting" exact="viral" post="entry Francis et al. [278] 2018-12-20 AU2015340134B2 Antigenic gene"/>
  <result pre="[279] 2018-01-30 US9878024B2 Enhanced immune response Methods and compositions using" exact="Listeria" post="for enhancing immunogenicity by prime-boost Provided herein are prime-boost"/>
  <result pre="virus, a Togaviridae virus, a Hepeviridae virus and a Bunyaviridae" exact="virus infection" post="with one or more nucleosides, nucleotides and nucleotide analogue"/>
  <result pre="a Togaviridae virus, a Hepeviridae virus and a Bunyaviridae virus" exact="infection" post="with one or more nucleosides, nucleotides and nucleotide analogue"/>
  <result pre="US10286065B2 Treatment and immune modulators Compositions and methods for treating" exact="viral" post="infections through stimulated innate immunity in combination with antiviral"/>
  <result pre="Treatment and immune modulators Compositions and methods for treating viral" exact="infections" post="through stimulated innate immunity in combination with antiviral compounds"/>
  <result pre="compounds Embodiments are directed to compositions and methods for treating" exact="viral" post="infections Dickey et al. [285] 2019-10-09 EP3194423B1 Treatment antiviral"/>
  <result pre="Embodiments are directed to compositions and methods for treating viral" exact="infections" post="Dickey et al. [285] 2019-10-09 EP3194423B1 Treatment antiviral Method"/>
  <result pre="as a vaccine for treating and preventing disease, such as" exact="infectious" post="bronchitis, in a subject Bickerton et al. [287] Specifically,"/>
  <result pre="of AbbvieÂ®. They are patented for use against viruses (Ebola)," exact="malaria" post="and HIV/AIDS, respectively, however, have shown potential for application"/>
  <result pre="high toll rates alone in China itself, most likely. The" exact="infection" post="is spreading across the globe. There are no licensed"/>
  <result pre="Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D:" exact="Severe" post="acute respiratory syndrome-related coronavirus: the species and its virusesâ€&quot;a"/>
  <result pre="BL, Lauber C, Leontovich AM, Neuman BW, Penzar D: Severe" exact="acute" post="respiratory syndrome-related coronavirus: the species and its virusesâ€&quot;a statement"/>
  <result pre="Lauber C, Leontovich AM, Neuman BW, Penzar D: Severe acute" exact="respiratory" post="syndrome-related coronavirus: the species and its virusesâ€&quot;a statement of"/>
  <result pre="the ecology of This emerging diseaseAdv Anim Vet Sci202083234237 3.Bonilla-AldanaDKHolguin-RiveraYCortes-BonillaICardona-TrujilloMCGarcia-BarcoABedoya-AriasHARabaanAASahRRodriguez-MoralesAJCoronavirus" exact="infections" post="reported by ProMED, February 2000â€&quot;January 2020Travel Med Infect Dis202098101575"/>
  <result pre="Travel Medicine (SLAMVI)Travel Med Infect Dis20203310156732006657 8.collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (â€ŽCOVID-19)â€Ž: situation report, 552020GenevaWorld Health Organization 9.YangYPengFWangRGuanKJiangTXuGSunJChangCThe deadly"/>
  <result pre="to Covid-19â€&quot;a once-in-a-century pandemic?N Engl J Med2020382181677167932109012 11.Bonilla-AldanaDKVillamil-GÃ³mezWERabaanAARodriguez-MoralesAJUna nueva zoonosis" exact="viral" post="de preocupaciÃ³n global: COVID-19, enfermedad por coronavirus 2019Iatreia2020332107110 12.Al-TawfiqJAGautretPAsymptomatic"/>
  <result pre="preocupaciÃ³n global: COVID-19, enfermedad por coronavirus 2019Iatreia2020332107110 12.Al-TawfiqJAGautretPAsymptomatic Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) infection: extent and implications for infection"/>
  <result pre="global: COVID-19, enfermedad por coronavirus 2019Iatreia2020332107110 12.Al-TawfiqJAGautretPAsymptomatic Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) infection: extent and implications for infection control:"/>
  <result pre="East Respiratory Syndrome Coronavirus (MERS-CoV) infection: extent and implications for" exact="infection" post="control: A systematic reviewTravel Med Infect Dis201927273230550839 13.BaharoonSMemishZAMERS-CoV as"/>
  <result pre="A systematic reviewTravel Med Infect Dis201927273230550839 13.BaharoonSMemishZAMERS-CoV as an emerging" exact="respiratory" post="illness: a review of prevention methodsTravel Med Infect Dis201932101520"/>
  <result pre="Virol202092443344031967321 17.Bonilla-AldanaDKJimenez-DiazSDArango-DuqueJSAguirre-FlorezMBalbin-RamonGJPaniz-MondolfiASuÃ¡rezJAPacharMRPerez-GarciaLADelgado-NogueraLAet al.Bats in ecosystems and their wide spectrum of" exact="viral" post="infectious threats: SARS-CoV-2 and other emerging virusesInt J Infect"/>
  <result pre="17.Bonilla-AldanaDKJimenez-DiazSDArango-DuqueJSAguirre-FlorezMBalbin-RamonGJPaniz-MondolfiASuÃ¡rezJAPacharMRPerez-GarciaLADelgado-NogueraLAet al.Bats in ecosystems and their wide spectrum of viral" exact="infectious" post="threats: SARS-CoV-2 and other emerging virusesInt J Infect Dis.202010.1016/j.ijid.2020.08.05032829048"/>
  <result pre="threats: what lessons have we learned?Int J Epidemiol.202049371772632086938 20.RamadanNShaibHMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): a reviewGerms201991354231119115 21.VijayanandPWilkinsEWoodheadMSevere acute respiratory syndrome"/>
  <result pre="what lessons have we learned?Int J Epidemiol.202049371772632086938 20.RamadanNShaibHMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): a reviewGerms201991354231119115 21.VijayanandPWilkinsEWoodheadMSevere acute respiratory syndrome (SARS):"/>
  <result pre="Epidemiol.202049371772632086938 20.RamadanNShaibHMiddle East respiratory syndrome coronavirus (MERS-CoV): a reviewGerms201991354231119115 21.VijayanandPWilkinsEWoodheadMSevere" exact="acute" post="respiratory syndrome (SARS): a reviewClin Med (Lond)20044215216015139736 22.LiuJZhengXTongQLiWWangBSutterKTrillingMLuMDittmerUYangDOverlapping and"/>
  <result pre="20.RamadanNShaibHMiddle East respiratory syndrome coronavirus (MERS-CoV): a reviewGerms201991354231119115 21.VijayanandPWilkinsEWoodheadMSevere acute" exact="respiratory" post="syndrome (SARS): a reviewClin Med (Lond)20044215216015139736 22.LiuJZhengXTongQLiWWangBSutterKTrillingMLuMDittmerUYangDOverlapping and discrete"/>
  <result pre="East respiratory syndrome coronavirus (MERS-CoV): a reviewGerms201991354231119115 21.VijayanandPWilkinsEWoodheadMSevere acute respiratory" exact="syndrome" post="(SARS): a reviewClin Med (Lond)20044215216015139736 22.LiuJZhengXTongQLiWWangBSutterKTrillingMLuMDittmerUYangDOverlapping and discrete aspects"/>
  <result pre="Wuhan, China, of novel Coronavirus-infected pneumoniaN Engl J Med2020382131199120731995857 24.DhamaKKhanSTiwariRSircarSBhatSMalikYSSinghKPChaicumpaWBonilla-AldanaDKRodriguez-MoralesAJCoronavirus" exact="disease" post="2019-COVID-19Clin Microbiol Rev.2020334e00028-2032580969 25.HuangCWangYLiXRenLZhaoJHuYZhangLFanGXuJGuXet al.Clinical features of patients infected"/>
  <result pre="with the SARS-CoV-2 divergenceCurr Trop Med Rep.2020737578 30.Villamizar-PenaRGutierrez-OcampoERodriguez-MoralesAJPooled prevalence of" exact="diarrhea" post="among COVID-19 PatientsClin Gastroenterol Hepatol.202018102385238732425705 31.GuiMSongWZhouHXuJChenSXiangYWangXCryo-electron microscopy structures of"/>
  <result pre="for receptor bindingCell Res201727111912928008928 32.JiaZYanLRenZWuLWangJGuoJZhengLMingZZhangLLouZet al.Delicate structural coordination of the" exact="Severe" post="Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysisNucleic Acids"/>
  <result pre="receptor bindingCell Res201727111912928008928 32.JiaZYanLRenZWuLWangJGuoJZhengLMingZZhangLLouZet al.Delicate structural coordination of the Severe" exact="Acute" post="Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400"/>
  <result pre="bindingCell Res201727111912928008928 32.JiaZYanLRenZWuLWangJGuoJZhengLMingZZhangLLouZet al.Delicate structural coordination of the Severe Acute" exact="Respiratory" post="Syndrome coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400 33.Galasiti"/>
  <result pre="Res201727111912928008928 32.JiaZYanLRenZWuLWangJGuoJZhengLMingZZhangLLouZet al.Delicate structural coordination of the Severe Acute Respiratory" exact="Syndrome" post="coronavirus Nsp13 upon ATP hydrolysisNucleic Acids Res201947126538655031131400 33.Galasiti KankanamalageACKimYDamalankaVCRathnayakeADFehrARMehzabeenNBattaileKPLovellSLushingtonGHPerlmanSet"/>
  <result pre="recent developmentsVet Q2020401687632036774 40.ZhuNZhangDWangWLiXYangBSongJZhaoXHuangBShiWLuRet al.A Novel Coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med2020382872773331978945 41.Wang M, Wu"/>
  <result pre="8274 samples with 2019-novel coronavirus in Wuhan. medRxiv. 2020:2020.2002.2012.20022327. 42.Panduro-CorreaVArteaga-LiviasKRodrÃ­guez-MoralesAJCoronavirus" exact="disease" post="2019 (COVID-19) and surgical recommendations in Latin AmericaAm Surg.202086659659832683976"/>
  <result pre="al. Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. bioRxiv."/>
  <result pre="55.Redfield R. Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus. In:" exact="American" post="Society for Microbiology; 2020. 56.Shen K, Yang Y, Wang"/>
  <result pre="et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statement. World J Pediatr. 2020."/>
  <result pre="camels, Eastern Africa, 1983â€&quot;1997Emerg Infect Dis201420122093209525425139 61.EllwangerJHChiesJABZoonotic spillover and emerging" exact="viral" post="diseases time to intensify zoonoses surveillance in BrazilBraz J"/>
  <result pre="of SARS2020In. GenevaWorld Health, Organization 64.collab: World Health OrganizationMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)2020GenevaWorld Health Organization 65.World Health O: Clinical"/>
  <result pre="SARS2020In. GenevaWorld Health, Organization 64.collab: World Health OrganizationMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)2020GenevaWorld Health Organization 65.World Health O: Clinical management"/>
  <result pre="(MERS-CoV)2020GenevaWorld Health Organization 65.World Health O: Clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus; infection is suspected: interim"/>
  <result pre="Health Organization 65.World Health O: Clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus; infection is suspected: interim guidance,"/>
  <result pre="Organization 65.World Health O: Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus; infection is suspected: interim guidance, 28"/>
  <result pre="Clinical management of severe acute respiratory infection when novel coronavirus;" exact="infection" post="is suspected: interim guidance, 28 January 2020. Geneva: World"/>
  <result pre="America: the case of BrazilBraz J Infect Dis2020242939532335078 68.MalikYSKumarNSircarSKaushikRBhatSDhamaKGuptaPGoyalKSinghMPGhoshalUet al.Coronavirus" exact="Disease" post="Pandemic (COVID-19): challenges and a global perspectivePathogens202097 69.Li Z,"/>
  <result pre="members, and non-members of medical teams aiding in COVID-19 control." exact="Brain" post="Behav Immunity. 2020. 70.GutiÃ©rrezABRodrÃ­guez-MoralesAJNarvÃ¡ez MejÃ­aÃ�JGarcÃ­a PeÃ±aÃ�AGiraldo MontoyaÃ�MCortes MuÃ±ozAJGarcÃ­aALOspina SerranoAVEscobarBPAcevedo"/>
  <result pre="al.Colombian consensus recommendations for diagnosis, management and treatment of the" exact="infection" post="by SARS-COV-2/ COVID-19 in health care facilities - Recommendations"/>
  <result pre="F, Liu J, Yip CC-Y, Poon RW-S et al: A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="Yip CC-Y, Poon RW-S et al: A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="Biol20203071346135132197085 74.Features, Evaluation and Treatment Coronavirus (COVID-19). https://www.ncbi.nlm.nih.gov/books/NBK554776/. 75.LuHStrattonCWTangY-WOutbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: The mystery and"/>
  <result pre="2020; 132(6):1346-1361. 83.GuoY-RCaoQ-DHongZ-STanY-YChenS-DJinH-JTanK-SWangD-YYanYThe origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreak - an update on the statusMil"/>
  <result pre="of the2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 88.Yu L, Wu S,"/>
  <result pre="the2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect20209122123631987001 88.Yu L, Wu S,"/>
  <result pre="iLACO. medRxiv 2020:2020.2002.2020.20025874. 89.ZhangNWangLDengXLiangRSuMHeCHuLSuYRenJYuFet al.Recent advances in the detection of" exact="respiratory" post="virus infection in humansJ Med Virol202092440841731944312 90.CormanVEckerleIBleickerTZakiALandtOEschbach-BludauMvan BoheemenSGopalRBallhauseMBestebroerTDetection of"/>
  <result pre="medRxiv 2020:2020.2002.2020.20025874. 89.ZhangNWangLDengXLiangRSuMHeCHuLSuYRenJYuFet al.Recent advances in the detection of respiratory" exact="virus infection" post="in humansJ Med Virol202092440841731944312 90.CormanVEckerleIBleickerTZakiALandtOEschbach-BludauMvan BoheemenSGopalRBallhauseMBestebroerTDetection of a novel"/>
  <result pre="2020:2020.2002.2020.20025874. 89.ZhangNWangLDengXLiangRSuMHeCHuLSuYRenJYuFet al.Recent advances in the detection of respiratory virus" exact="infection" post="in humansJ Med Virol202092440841731944312 90.CormanVEckerleIBleickerTZakiALandtOEschbach-BludauMvan BoheemenSGopalRBallhauseMBestebroerTDetection of a novel"/>
  <result pre="B-L. Clinical and computed tomographic imaging features of novel coronavirus" exact="pneumonia" post="caused by SARS-CoV-2. J Infect. 2020. 93.WangWXuYGaoRLuRHanKWuGTanWDetection of SARS-CoV-2"/>
  <result pre="chloroquine phosphate for the treatment of novel coronavirus pneumoniaChin J" exact="Tuberculosis" post="Respir Dis2020433185188 102.LiHWangYMXuJYCaoBPotential antiviral therapeutics for 2019 Novel CoronavirusChin"/>
  <result pre="Respir Dis2020433185188 102.LiHWangYMXuJYCaoBPotential antiviral therapeutics for 2019 Novel CoronavirusChin J" exact="Tuberculosis" post="Respir Dis2020433170172 103.Di PierroFBertuccioliACavecchiaIPossible therapeutic role of a highly"/>
  <result pre="Dietol202010.23736/s21121-23421x.23720.02697-2373532397695 104.NishiuraHMizumotoKVillamil-GomezWERodriguez-MoralesAJPreliminary estimation of the basic reproduction number of Zika" exact="virus infection" post="during Colombia epidemic, 2015-2016Travel Med Infect Dis201614327427627060613 105.Rodriguez-MoralesAJZika and"/>
  <result pre="104.NishiuraHMizumotoKVillamil-GomezWERodriguez-MoralesAJPreliminary estimation of the basic reproduction number of Zika virus" exact="infection" post="during Colombia epidemic, 2015-2016Travel Med Infect Dis201614327427627060613 105.Rodriguez-MoralesAJZika and"/>
  <result pre="infection during Colombia epidemic, 2015-2016Travel Med Infect Dis201614327427627060613 105.Rodriguez-MoralesAJZika and" exact="microcephaly" post="in Latin America: An emerging threat for pregnant travelers?Travel"/>
  <result pre="Infect Dis20161415626879565 106.QiuHBLiXYDuBKangHYJWangYSWangFSunBTongZHThe keypoints in treatment of the critical coronavirus" exact="disease" post="2019 patient(1)Zhonghua Jie He He Hu Xi Za Zhi202043427327732087621"/>
  <result pre="110.ChanJFWYaoYYeungMLDengWBaoLJiaLLiFXiaoCGaoHYuPet al.Treatment With Lopinavir/Ritonavir or Interferon-Î²1b Improves Outcome of MERS-CoV" exact="Infection" post="in a Nonhuman Primate Model of Common MarmosetJ Infect"/>
  <result pre="(CTAP). https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap. Accessed 13 Aug 2020. 114.Millan-OnateJMillanWMendozaLASanchezCGFernandez-SuarezHBonilla-AldanaDKRodriguez-MoralesAJSuccessful recovery of COVID-19" exact="pneumonia" post="in a patient from Colombia after receiving chloroquine and"/>
  <result pre="chloroquine and clarithromycinAnn Clin Microbiol Antimicrob20201911632331519 115.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic Treatments for Coronavirus" exact="Disease" post="2019 (COVID-19): A ReviewJAMA20203231818241836 116.TortoriciMAVeeslerDStructural insights into coronavirus entryAdv"/>
  <result pre="Med200410887187515247913 118.ChenZBaoLChenCZouTXueYLiFLvQGuSGaoXCuiSet al.Human neutralizing monoclonal antibody inhibition of middle east" exact="respiratory" post="syndrome coronavirus replication in the common marmosetJ Infect Dis2017215121807181528472421"/>
  <result pre="118.ChenZBaoLChenCZouTXueYLiFLvQGuSGaoXCuiSet al.Human neutralizing monoclonal antibody inhibition of middle east respiratory" exact="syndrome" post="coronavirus replication in the common marmosetJ Infect Dis2017215121807181528472421 119.WangLShiWChappellJDJoyceMGZhangYKanekiyoMBeckerMMvan"/>
  <result pre="monoclonal antibodies targeting multiple antigenic sites on the middle east" exact="respiratory" post="syndrome coronavirus spike glycoprotein to avoid neutralization escapeJ Virol20189210e02002e0201729514901"/>
  <result pre="antibodies targeting multiple antigenic sites on the middle east respiratory" exact="syndrome" post="coronavirus spike glycoprotein to avoid neutralization escapeJ Virol20189210e02002e0201729514901 120.YuFDuLOjciusDMPanCJiangSMeasures"/>
  <result pre="to avoid neutralization escapeJ Virol20189210e02002e0201729514901 120.YuFDuLOjciusDMPanCJiangSMeasures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
  <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, ChinaMicrobes Infect2020222747932017984 121.LiuCZhouQLiYGarnerLVWatkinsSPCarterLJSmootJGreggACDanielsADJerveySet al.Research and"/>
  <result pre="Ebola epidemic crystallizes the potential of passive antibody therapy for" exact="infectious" post="diseasesPLoS Pathog2015114e100471725905897 125.KeckZ-YWangYLauPFoungSKHIsolation of HCV neutralizing antibodies by yeast"/>
  <result pre="HCV neutralizing antibodies by yeast displayMethods Mol Biol2019191139541930593641 126.ShinYWChangK-HHongG-WYeoS-GJeeYKimJ-HOhM-DChoD-HKimS-HSelection of" exact="vaccinia" post="virus-neutralizing antibody from a phage-display human-antibody libraryJ Microbiol Biotechnol201929465165730856707"/>
  <result pre="SystemsKona201633638527081214 131.ThiEPLeeACHGeisbertJBUrsic-BedoyaRAgansKNRobbinsMDeerDJFentonKAKondratowiczASMacLachlanIet al.Rescue of non-human primates from advanced Sudan ebolavirus" exact="infection" post="with lipid encapsulated siRNANat Microbiol2016110161421614227670117 132.ThiEPMireCELeeACHGeisbertJBZhouJZAgansKNSneadNMDeerDJBarnardTRFentonKAet al.Lipid nanoparticle siRNA"/>
  <result pre="of Ebola-virus-Makona-infected nonhuman primatesNature2015521755236236525901685 133.DunningJSahrFRojekAGannonFCarsonGIdrissBMassaquoiTGandiRJosephSOsmanHKet al.Experimental treatment of ebola virus" exact="disease" post="with TKM-130803: A Single-Arm Phase 2 Clinical TrialPLoS Med2016134e1001997e100199727093560"/>
  <result pre="COVID-19Travel Med Infect Dis20203410161510161532145386 135.RothanHAByrareddySNThe epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ Autoimmun202010910243332113704 136.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and chloroquine effectively inhibit the"/>
  <result pre="137.TangWCaoZHanMWangZChenJSunWWuYXiaoWLiuSChenEet al.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trialBMJ2020369m184932409561 138.BorbaMGSValFFASampaioVSAlexandreMAAMeloGCBritoMMouraoMPGBrito-SousaJDBaia-da-SilvaDGuerraMVFet al.Effect of"/>
  <result pre="of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized"/>
  <result pre="Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical"/>
  <result pre="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical TrialJAMA"/>
  <result pre="as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical TrialJAMA Netw"/>
  <result pre="al: Remdesivir for 5 or 10 Days in Patients with" exact="Severe" post="Covid-19. N Engl J Med. 2020. 145.Beigel JH, Tomashek"/>
  <result pre="2020. 156.PanXDongLYangLChenDPengCPotential drugs for the treatment of the novel coronavirus" exact="pneumonia" post="(COVID-19) in ChinaVirus Res202028619805732531236 157.SharunKDhamaKPatelSKPathakMTiwariRSinghBRSahRBonilla-AldanaDKRodriguez-MoralesAJLeblebiciogluHIvermectin, a new candidate therapeutic"/>
  <result pre="160.MireCEGeisbertJBAgansKNThiEPLeeACHFentonKAGeisbertTWPassive immunotherapy: assessment of convalescent serum against ebola virus makona" exact="infection" post="in nonhuman primatesJ Infect Dis2016214suppl 3S367S37427571900 161.FocosiDAndersonAOTangJWTuccoriMConvalescent plasma therapy"/>
  <result pre="immune serum in an experimental animal model for Middle East" exact="respiratory" post="syndrome coronavirus infectionJ Virol201589116117612025787284 163.MaranoGVaglioSPupellaSFaccoGCatalanoLLiumbrunoGMGrazziniGConvalescent plasma: new evidence for"/>
  <result pre="serum in an experimental animal model for Middle East respiratory" exact="syndrome" post="coronavirus infectionJ Virol201589116117612025787284 163.MaranoGVaglioSPupellaSFaccoGCatalanoLLiumbrunoGMGrazziniGConvalescent plasma: new evidence for an"/>
  <result pre="TKM-100802 and convalescent plasma in 2 patients with ebola virus" exact="disease" post="in the United StatesClin Infect Dis201561449650225904375 165.JinY-HCaiLChengZ-SChengHDengTFanY-PFangCHuangDHuangL-QHuangQet al.A rapid"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil Med Res2020714432029004 166.RobackJDGuarnerJConvalescent plasma to treat COVID-19:"/>
  <result pre="and challengesJAMA20203231615611562 167.AndersonJSchifferCLeeS-KSwanstromRViral protease inhibitorsHandb Exp Pharmacol200918918985110 168.Ching-HsiuTPei-YuLVictorSMei-LingLAntiviral therapy targeting" exact="viral" post="polymeraseCurr Pharm Des200612111339135516611119 169.ChuCMChengVCCHungIFNWongMMLChanKHChanKSKaoRYTPoonLLMWongCLPGuanYet al.Role of lopinavir/ritonavir in the"/>
  <result pre="and clinical findingsThorax200459325225614985565 170.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSKojanSAl JeraisyMDeebAMAssiriAMet al.Treatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
  <result pre="clinical findingsThorax200459325225614985565 170.ArabiYMAlothmanABalkhyHHAl-DawoodAAlJohaniSAl HarbiSKojanSAl JeraisyMDeebAMAssiriAMet al.Treatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
  <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBioScience Trends2020141646832037389 173.SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJMontgomerySAHoggABabusisDClarkeMOet"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBioScience Trends2020141727332074550 176.LinLLiTSInterpretation of â€œGuidelines for the"/>
  <result pre="â€œGuidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV)" exact="Infection" post="by the National Health Commission (Trial Version 5)â€�Zhonghua yi"/>
  <result pre="zhi20201001180580732234150 177.FanH-HWangL-QLiuW-LAnX-PLiuZ-DHeX-QSongL-HTongY-GRepurposing of clinically approved drugs for treatment of coronavirus" exact="disease" post="2019 in a 2019-novel coronavirus-related coronavirus modelChin Med J"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChemBioChem202021573073832022370 180.TonA-TGentileFHsingMBanFCherkasovARapid identification of potential"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChemBioChem202021573073832022370 180.TonA-TGentileFHsingMBanFCherkasovARapid identification of potential inhibitors"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChemBioChem202021573073832022370 180.TonA-TGentileFHsingMBanFCherkasovARapid identification of potential inhibitors of"/>
  <result pre="A review of the main histopathological findings in the Coronavirus" exact="Disease" post="2019 (COVID-19). Hum Pathol. 2020. 185.Lei C, Fu W,"/>
  <result pre="Acad Sci202011713700132165541 189.ZhangJZhouLYangYPengWWangWChenXTherapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinicsLancet Respir Med202083e11e1232061335 190.Macauley P, Martin A,"/>
  <result pre="right measures to control COVID-19Lancet Infect Dis202020552352432145766 195.MarraroGASpadaCConsideration of the" exact="respiratory" post="support strategy of severe acute respiratory failure caused by"/>
  <result pre="Infect Dis202020552352432145766 195.MarraroGASpadaCConsideration of the respiratory support strategy of severe" exact="acute" post="respiratory failure caused by SARS-CoV-2 infection in childrenZhongguo Dang"/>
  <result pre="Dis202020552352432145766 195.MarraroGASpadaCConsideration of the respiratory support strategy of severe acute" exact="respiratory" post="failure caused by SARS-CoV-2 infection in childrenZhongguo Dang Dai"/>
  <result pre="support strategy of severe acute respiratory failure caused by SARS-CoV-2" exact="infection" post="in childrenZhongguo Dang Dai Er Ke Za Zhi202022318319432204751 196.BaronSADevauxCColsonPRaoultDRolainJ-MTeicoplanin:"/>
  <result pre="on SARS-CoV immunological studies. bioRxiv 2020:2020.2002.2003.933226. 201.ShangWYangYRaoYRaoXThe outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesVaccines2020511832194995 202.PatelSKPathakMTiwariRYatooMIMalikYSSahRRabaanAASharunKDhamaKBonilla-AldanaDKet al.A vaccine is not"/>
  <result pre="studies. bioRxiv 2020:2020.2002.2003.933226. 201.ShangWYangYRaoYRaoXThe outbreak of SARS-CoV-2 pneumonia calls for" exact="viral" post="vaccinesVaccines2020511832194995 202.PatelSKPathakMTiwariRYatooMIMalikYSSahRRabaanAASharunKDhamaKBonilla-AldanaDKet al.A vaccine is not too far for"/>
  <result pre="https://www.niaid.nih.gov/diseases-conditions/coronaviruses-therapeutics-vaccines. 207.DRAFT landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. 208.WHO Coronavirus" exact="Disease" post="(COVID-19) Dashboard. https://covid19.who.int/. 209.KimYCDemaBReyes-SandovalACOVID-19 vaccines: breaking record times to"/>
  <result pre="A, Ulaszewska M et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaques. Nature. 2020. 211.Folegatti PM, Ewer KJ,"/>
  <result pre="we?Expert Rev Vaccines20098788789819538115 219.WuFZhaoSYuBChenY-MWangWSongZ-GHuYTaoZ-WTianJ-HPeiY-Yet al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature2020579779826526932015508 220.BukreyevALamirandeEWBuchholzUJVogelLNElkinsWRClaireMSMurphyBRSubbaraoKCollinsPLMucosal immunisation of African green monkeys"/>
  <result pre="Rev Vaccines20098788789819538115 219.WuFZhaoSYuBChenY-MWangWSongZ-GHuYTaoZ-WTianJ-HPeiY-Yet al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature2020579779826526932015508 220.BukreyevALamirandeEWBuchholzUJVogelLNElkinsWRClaireMSMurphyBRSubbaraoKCollinsPLMucosal immunisation of African green monkeys (Cercopithecus"/>
  <result pre="associated with human respiratory disease in ChinaNature2020579779826526932015508 220.BukreyevALamirandeEWBuchholzUJVogelLNElkinsWRClaireMSMurphyBRSubbaraoKCollinsPLMucosal immunisation of" exact="African" post="green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus"/>
  <result pre="2020. 225.FolegattiPMBittayeMFlaxmanALopezFRBellamyDKupkeAMairCMakinsonRSheridanJRohdeCet al.Safety and immunogenicity of a candidate Middle East" exact="respiratory" post="syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled,"/>
  <result pre="225.FolegattiPMBittayeMFlaxmanALopezFRBellamyDKupkeAMairCMakinsonRSheridanJRohdeCet al.Safety and immunogenicity of a candidate Middle East respiratory" exact="syndrome" post="coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase"/>
  <result pre="Park JS. Use of radotinib for prevention or treatment of" exact="viral" post="respiratory disease. 2017. 233.Radtke KL PH, Neyts J, Jochmans"/>
  <result pre="JS. Use of radotinib for prevention or treatment of viral" exact="respiratory" post="disease. 2017. 233.Radtke KL PH, Neyts J, Jochmans D,"/>
  <result pre="LE, Wirblich C, Coleman CM, Frieman MB. Multivalent vaccines for" exact="rabies" post="virus and coronaviruses. 2017 238.Sutter G FR, Volz A,"/>
  <result pre="S, Eickmann M. A novel vaccine against the middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV). 2016. 239.Brownlie J CV, Erles K."/>
  <result pre="Eickmann M. A novel vaccine against the middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV). 2016. 239.Brownlie J CV, Erles K. Spike"/>
  <result pre="2016. 239.Brownlie J CV, Erles K. Spike protein of canine" exact="respiratory" post="coronavirus (crcv), polymerase and hemaglutinin / esterase. 2012. 240.Wuhanâ€™s"/>
  <result pre="and hemaglutinin / esterase. 2012. 240.Wuhanâ€™s Much-Maligned Virology Institute Seeks" exact="Patent" post="on US Drug. http://www.sixthtone.com/news/1005169/wuhans-much-maligned-virology-institute-seeks-patent-on-us-drug. 241.Chinese firm copies Gileadâ€™s remdesivir,"/>
  <result pre="with severe ARDS by combining early mechanical ventilation and ECMO." exact="Heart" post="Lung. 2020. 249.OwjiHNegahdaripourMHajighahramaniNImmunotherapeutic approaches to curtail COVID-19Int Immunopharm.202023106924 250.Ibrahim"/>
  <result pre="et al: Metformin use is associated with increased incidence of" exact="acidosis" post="but not mortality in individuals with COVID-19 and pre-existing"/>
  <result pre="acidosis but not mortality in individuals with COVID-19 and pre-existing" exact="type 2" post="diabetes. Cell Metab. 2020. 257.YadavMDhagatSEswariJSEmerging strategies on in silico"/>
  <result pre="picornaviruses, caliciviruses, and coronaviruses. 2017. 262.Bickerton EKS, Britton P. Attenuated" exact="infectious" post="bronchitis virus. 2017. 263.Geall RK, Otten G, Mand CW."/>
  <result pre="caliciviruses, and coronaviruses. 2017. 262.Bickerton EKS, Britton P. Attenuated infectious" exact="bronchitis" post="virus. 2017. 263.Geall RK, Otten G, Mand CW. Delivery"/>
  <result pre="W, Joyce MG, Kanekiyo M, Mascola J. : Middle East" exact="Respiratory" post="Syndrome coronavirus immunogens, antibodies, and their use. 2016. 268.Liao"/>
  <result pre="Joyce MG, Kanekiyo M, Mascola J. : Middle East Respiratory" exact="Syndrome" post="coronavirus immunogens, antibodies, and their use. 2016. 268.Liao ZJ,"/>
  <result pre="and their use. 2016. 268.Liao ZJ, Li J, Kaikun LM." exact="Avian" post="infectious bronchitis virus natural mutant. 2016. 269.Shibo JXL, Qian"/>
  <result pre="their use. 2016. 268.Liao ZJ, Li J, Kaikun LM. Avian" exact="infectious" post="bronchitis virus natural mutant. 2016. 269.Shibo JXL, Qian W,"/>
  <result pre="use. 2016. 268.Liao ZJ, Li J, Kaikun LM. Avian infectious" exact="bronchitis" post="virus natural mutant. 2016. 269.Shibo JXL, Qian W, Fei"/>
  <result pre="Y: Suppress polypeptide and its application of human coronary virusâ€™s" exact="infection" post="wide spectrum. 2017. 270.Jiang S DL, Zhou Y, Zhao"/>
  <result pre="271.Kyratsous C SN, Sivapalasingam S: Human antibodies to middle east" exact="respiratory" post="syndrome - coronavirus spike protein. 2019. 272.Gray S. AAV"/>
  <result pre="C SN, Sivapalasingam S: Human antibodies to middle east respiratory" exact="syndrome" post="- coronavirus spike protein. 2019. 272.Gray S. AAV vectors"/>
  <result pre="spike protein. 2019. 272.Gray S. AAV vectors targeted to the" exact="central nervous system." post="2019. 273.Thomsen AR, Grujic M. Priming of an immune"/>
  <result pre="D, Scott B, Tuvim M. Compositions and methods for treating" exact="viral" post="infections through stimulated innate immunity in combination with antiviral"/>
  <result pre="Scott B, Tuvim M. Compositions and methods for treating viral" exact="infections" post="through stimulated innate immunity in combination with antiviral compounds."/>
  <result pre="JN, Kay MS. Methods and compositions related to inhibition of" exact="viral" post="entry. 2019. 279.Jung IY, Lee HY, Lee H. Microfluidic"/>
  <result pre="TW BJ, Leong MLL, Bahjat KS. Methods and compositions using" exact="Listeria" post="for enhancing immunogenicity by prime boost. 2018. 281.Brennan MB,"/>
  <result pre="D, Scott B, Tuvim M: Compositions and methods for treating" exact="viral" post="infections through stimulated innate immunity in combination with antiviral"/>
  <result pre="Scott B, Tuvim M: Compositions and methods for treating viral" exact="infections" post="through stimulated innate immunity in combination with antiviral compounds."/>
 </snippets>
</snippetsTree>
